TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9192551
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no oral care instructions)
Study: 9192551
Drug: E1 protocol
Normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: E1 protocol (oral care instructions at 1 day before radiotherapy)
Study: 8237937
Drug: alpha-interferon (alfa-2b,
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha-interferon (alfa-2b, 10 million units three times weekly)
Study: 4035073
Drug: Short course
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short course of cyclophosphamide IV 5 mg/kg daily for 6 days immediately after mastectomy
Study: 4035073
Drug: Delayed adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed adjuvant course of cyclophosphamide IV 5 mg/kg daily for 6 days given 2-4 weeks after mastectomy
Study: 4035073
Drug: Prolonged treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged treatment with IV CMF for 1 year
Study: 28074489
Drug: Edasalonexent (6000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edasalonexent (6000 mg)
Study: 28074489
Drug: Edasalonexent (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edasalonexent (single dose)
Study: 9643160
Drug: Lacidipine 4
Normalized name: lacidipine 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacidipine 4 mg or 6 mg with Hydrochlorothiazide 25 mg added
Study: 30569637
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose NS-0200 (1.1 g leucine/0.5 g metformin/1.0 mg sildenafil)
Study: 28345429
Drug: Intravenous 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 1000 mg uric acid
Study: 25963345
Drug: Uptitrated Metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uptitrated Metformin
Study: 23659360
Drug: Both stimulants
Normalized name: Staphylococcus simulans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both stimulants
Study: 23659360
Drug: Shift from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shift from inferior drug to best drug
Study: 9402845
Drug: CEOP/IMVP-Dexa chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEOP/IMVP-Dexa chemotherapy and filgrastim (self-injected at 5 micrograms/kg body weight s.c. daily, except on cytotoxic drug days)
Study: 9402845
Drug: CEOP/IMVP-Dexa chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEOP/IMVP-Dexa chemotherapy alone
Study: 7687509
Drug: Relevant foods
Normalized name: Levant cottonseed oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relevant foods (foods eliciting positive skin-prick tests and positive oral challenges)
Study: 7687509
Drug: Non-relevant foods
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-relevant foods (foods eliciting positive skin tests but negative oral challenges)
Study: 3323262
Drug: Trimipramine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimipramine (up to 100 mg twice daily)
Study: 3323262
Drug: Amitriptyline (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (up to 100 mg twice daily)
Study: 30415890
Drug: Oral inosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral inosine treatment
Study: 6660435
Drug: Intranasal verapamil,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal verapamil, 1 mg
Study: 31725644
Drug: Chaihu-Shugan-San (CHSGS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chaihu-Shugan-San (CHSGS) capsule
Study: 31725644
Drug: Tadalafil oral
Normalized name: tadalafil Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil oral pharmacotherapy
Study: 31725644
Drug: CHSGS capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHSGS capsule
Study: 28735699
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (Coping Cat)
Study: 28735699
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of medication and cognitive-behavioral therapy
Study: 21645330
Drug: Multicomponent pharmacological
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multicomponent pharmacological management protocol for delirium (PMD) including low-dose haloperidol at 0.5-1 mg for 7 days
Study: 11815505
Drug: Sulfonylurea +
Normalized name: sulfanilylurea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfonylurea + insulin
Study: 7575256
Drug: Fortified antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fortified antibiotics (1.5% tobramycin and 10.0% cefazolin solutions)
Study: 2248109
Drug: Systematic exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systematic exposure to drug-related cues
Study: 2248109
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment for drug dependence
Study: 6305670
Drug: ranitidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: ranitidine (150 mg bid)
Study: 31389755
Drug: Immediate loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate loading of implants (n = 10)
Study: 31389755
Drug: Delayed loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed loading of implants (n = 10)
Study: 28090335
Drug: Top-down treatment
Normalized name: Hongo Killer Treatment Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Top-down treatment
Study: 27762512
Drug: Noradrenaline (0.5-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noradrenaline (0.5-3 mg/h)
Study: 27762512
Drug: Terlipressin (0.5-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terlipressin (0.5-2 mg/6h)
Study: 21294404
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg simvastatin in the morning
Study: 21294404
Drug: Evening simvastatin
Normalized name: Evenity
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Evening simvastatin administration
Study: 17506592
Drug: Clodronic acid
Normalized name: Clodronic acid
DrugBank: Clodronic acid (DB00720)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronic acid 800 mg plus elemental calcium 500 mg and 400 IU of vitamin D daily
Study: 15767608
Drug: Home-based balance-training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based balance-training program using a wobble board for 6 weeks (daily) and 6 months (weekly)
Study: 12093429
Drug: Plant stanol
Normalized name: plant stanol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant stanol ester (PSE) spread, 2 g daily for 4 weeks
Study: 12093429
Drug: Plant stanol
Normalized name: plant stanol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant stanol ester (PSE) spread, 3 g daily
Study: 7477146
Drug: Exercise plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise plus antihypertensive medication
Study: 2011406
Drug: Molsidomine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molsidomine (4 mg once acutely, 3 times 4 mg a day for 3 weeks)
Study: 2011406
Drug: Molsidomine (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molsidomine (after 3 weeks treatment)
Study: 7009019
Drug: Pyridoxine hydrochloride
Normalized name: Pyridoxine Hydrochloride
DrugBank: Pyridoxine phosphate (DB02209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pyridoxine hydrochloride (20 mgs twice daily)
Study: 30389226
Drug: Low-dose VWG
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose VWG OIT (1445 mg of wheat protein)
Study: 30389226
Drug: High-dose VWG
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose VWG OIT (maximum, 2748 mg of wheat protein)
Study: 30389226
Drug: Low-dose VWG
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose VWG OIT
Study: 25039364
Drug: Alemtuzumab induction
Normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Alemtuzumab induction therapy with reduced doses of tacrolimus, steroids, and mycophenolate mofetil
Study: 25039364
Drug: Thymoglobulin in
Normalized name: Thymoglobulin Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymoglobulin in association with standard dose immunosuppression (IS)
Study: 21824444
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg HCA with a high-carbohydrate meal (2 g carbohydrate/kg body weight, 80 % carbohydrate, 8 % fat, 12 % protein)
Study: 21824444
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg HCA with a high-carbohydrate meal
Study: 20818193
Drug: Exercise on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise on Prescription (EP)
Study: 16973659
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg intravitreal triamcinolone (ivTA)
Study: 16973659
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg intravitreal triamcinolone (ivTA)
Study: 16973659
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg intravitreal triamcinolone (ivTA)
Study: 15718403
Drug: Microgravity (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microgravity (0 G)
Study: 15718403
Drug: Hypergravity (1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypergravity (1.8 G)
Study: 15718403
Drug: Normal gravity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal gravity (1 G)
Study: 15718403
Drug: Hypergravity (1.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypergravity (1.7 G)
Study: 12111110
Drug: Fludarabine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine treatment (25 mg/m² daily for 5 days every 28 days)
Study: 10502181
Drug: Contrast-enhanced EUS
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast-enhanced EUS with air-filled albumin (0.22 mL/kg) intravenously injected at a rate of 1 mL/sec for 10 minutes
Study: 7560251
Drug: Dolasetron (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolasetron (0.6 to 5.0 mg/kg)
Study: 7560251
Drug: Dolasetron (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolasetron (doses > or = 3.0 mg/kg)
Study: 31274484
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate infusion (15 mg/kg) started 20 min before induction, during surgery, and for the first postoperative 24 hours.
Study: 31274484
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate infusion (15 mg/kg).
Study: 28599889
Drug: Thiopentone (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopentone (7.5 mg kg−1)
Study: 28599889
Drug: Propofol (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (3 mg kg−1)
Study: 28599889
Drug: Alfaxalone (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfaxalone (1.5 mg kg−1)
Study: 8633935
Drug: Triiodothyronine (T3)
DrugBank: Liothyronine (DB00279)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triiodothyronine (T3) treatment
Study: 1533530
Drug: terfenadine 120
Normalized name: terfenadine 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: terfenadine 120 mg
Study: 3880657
Drug: Vincristine (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vincristine (0.4 mg/m2/1/day by continuous infusion)
Study: 3880657
Drug: Vinblastine (1.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinblastine (1.7 mg/m2/1/day by continuous infusion)
Study: 3880657
Drug: Vindesine (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vindesine (1.2 mg/m2/1/day by continuous infusion)
Study: 3880657
Drug: Vindesine (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vindesine (1.2 mg/m2/1/day intermittent bolus)
Study: 29511334
Drug: D-amphetamine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-amphetamine (20 mg oral)
Study: 29511334
Drug: Methamphetamine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methamphetamine (20 mg oral)
Study: 25944519
Drug: Combination 17β-estradiol/progesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination 17β-estradiol/progesterone capsule
Study: 16492849
Drug: Programmed Intermittent
Normalized name: Program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Programmed Intermittent Epidural Bolus (PIEB) - 6 mL bolus every 30 min starting 45 min after intrathecal injection
Study: 16492849
Drug: Continuous Epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous Epidural Infusion (CEI) - 12 mL/h infusion starting 15 min after intrathecal injection
Study: 7818648
Drug: Bendrofluazide 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendrofluazide 1.25 mg and 5.0 mg
Study: 2453895
Drug: Hydromorphone (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromorphone (6 mg)
Study: 2453895
Drug: Naloxone (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (0.2 mg)
Study: 2453895
Drug: Buprenorphine 0.2
Normalized name: buprenorphine 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine 0.2 mg plus Naloxone 0.2 mg
Study: 2453895
Drug: Buprenorphine 0.3
Normalized name: buprenorphine 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine 0.3 mg plus Naloxone 0.2 mg
Study: 27011262
Drug: Intravitreal bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal bevacizumab (IVB) 0.25 mg/0.01 ml
Study: 27011262
Drug: Intravitreal bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal bevacizumab (IVB) 0.625 mg/0.025 ml
Study: 27978532
Drug: Ibuprofen 200mg
Normalized name: IBUPROFEN 200MG CAP
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 200mg plus paracetamol 325mg TID
Study: 27978532
Drug: Ibuprofen 400mg
Normalized name: IBUPROFEN 400MG TAB
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 400mg TID
Study: 25969894
Drug: MenABCWY formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenABCWY formulations containing OMV components
Study: 25969894
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of OMV‐containing MenABCWY formulations
Study: 22244384
Drug: Bio‐Oss Collagen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bio‐Oss Collagen with implant placement (Group 1)
Study: 22244384
Drug: Bio‐Oss Collagen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bio‐Oss Collagen without implant placement (Group 2)
Study: 10480420
Drug: MMF-based triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMF-based triple therapy (1.0 g of MMF twice daily from postoperative day 2, n=50)
Study: 10480420
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (CsA-Neoral and steroids, n=50)
Study: 7681647
Drug: Rapid antigen
Normalized name: INDICAID COVID-19 Rapid Antigen Home Test
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid antigen detecting test and a 10-day oral penicillin course
Study: 7681647
Drug: Rapid antigen
Normalized name: INDICAID COVID-19 Rapid Antigen Home Test
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid antigen detecting test and intramuscular benzathin penicillin G
Study: 7681647
Drug: Intramuscular benzathin
Normalized name: Benzaclin
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular benzathin penicillin G for all children with pharyngitis
Study: 26288118
Drug: mirabegron 50
Normalized name: mirabegron 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: mirabegron 50 mg/day
Study: 26288118
Drug: tolterodine ER
Normalized name: tolterodine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: tolterodine ER 4 mg/day
Study: 24899242
Drug: Mindfulness training
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mindfulness training program (weekly group-based classes in mindfulness practice, 2 ½ hours, for 8 weeks plus a 7-hour Saturday session in Week 6)
Study: 22235059
Drug: Action observation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Action observation (EG) - watching video footage of daily routine tasks and imitating movements for 2 minutes with therapist assistance.
Study: 15782753
Drug: Prescription for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription for nicotine patches
Study: 7577208
Drug: Cisplatin plus
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin plus etoposide (standard chemotherapy)
Study: 3083100
Drug: Hyperventilation at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperventilation at normal rate and tidal volume of 1.5 l
Study: 3083100
Drug: Hyperventilation at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperventilation at rate 24/min and tidal volume of 1.5 l
Study: 3083100
Drug: Hyperventilation at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperventilation at rate 24/min and tidal volume of 1.4 l
Study: 30251010
Drug: CoQ10 supplementation
Normalized name: CoQ10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CoQ10 supplementation (120 mg/day)
Study: 28081351
Drug: Methylprednisolone 5
Normalized name: methylprednisolone 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone 5 mg/kg
Study: 22162533
Drug: Istradefylline (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Istradefylline (20 to 40 mg/d)
Study: 22162533
Drug: Istradefylline (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Istradefylline (40 mg/d)
Study: 22162533
Drug: Istradefylline (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Istradefylline (dose increase)
Study: 18555813
Drug: Drospirenone 3
Normalized name: drospirenone 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drospirenone 3 mg / Ethinylestradiol 20 mcg in a 24/4 regimen
Study: 15756154
Drug: Epidural administration
Normalized name: epidural administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural administration of naropina 0.2%+fentanyl 4 microg/mL by elastomeric pump (rate 5 ml/h)
Study: 15756154
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of tramadol 600 mg+ketorolac trometamina 120 mg+ranitidina 200 mg+ondansetron 16 mg by elastomeric pump (rate 5 ml/h for 48 hours)
Study: 12427649
Drug: simvastatin plus
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: simvastatin plus 600 mg/d vitamin E
Study: 10320598
Drug: Paracetamol elixir
Normalized name: Soul Pattinson Childrens Paracetamol Elixir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol elixir (40 mg x kg(‐1)) 90 min before surgery
Study: 10320598
Drug: Paracetamol suppositories
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol suppositories (40 mg x kg(‐1)) intraoperatively
Study: 7588352
Drug: Fluconazole (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (3 mg/kg/daily per os)
Study: 7588352
Drug: Flucytosine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flucytosine (100 mg/kg/daily per os)
Study: 30957170
Drug: 8 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8 weeks of grazoprevir/elbasvir therapy
Study: 30957170
Drug: 12 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12 weeks of grazoprevir/elbasvir therapy
Study: 30957170
Drug: 8 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8 weeks of grazoprevir/elbasvir therapy with high HCV-1b load (≥1,500,000 IU/mL)
Study: 30957170
Drug: 8 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8 weeks of grazoprevir/elbasvir therapy with baseline Y93H RAS frequency >15%
Study: 30957170
Drug: 12 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12 weeks of grazoprevir/elbasvir therapy with high HCV-1b load and baseline Y93H RAS frequency >15%
Study: 26596997
Drug: Family Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family Therapy with Family Meal Intervention (FTFM)
Study: 26596997
Drug: Family Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family Therapy without Family Meal Intervention (FT)
Study: 23420115
Drug: Theobromine 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theobromine 250 mg
Study: 23420115
Drug: Theobromine 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theobromine 500 mg
Study: 23420115
Drug: Theobromine 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theobromine 1000 mg
Study: 21536693
Drug: Switch to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switch to monotherapy
Study: 19401662
Drug: Increased tidal
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased tidal volume (from 6 to 10 ml kg(‐1))
Study: 16963248
Drug: High-dose purified
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose purified soy isoflavones (genistein, 558 mg/day; daidzein, 296 mg/day; glycitein, 44 mg/day) for 84 days
Study: 16963248
Drug: High-dose purified
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose purified soy isoflavones
Study: 15783119
Drug: Isoniazid (INH)
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoniazid (INH) 300 mg with pyridoxine 20 mg daily for 1 year or until TB development
Study: 7873469
Drug: Beta-blockers or
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockers or calcium antagonists (used in association with nitrates)
Study: 3348157
Drug: Multivitamin-mineral supplement
Normalized name: Mineral Oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivitamin-mineral supplement providing 0.5 mg/d vitamin B-6
Study: 28442892
Drug: Sildenafil 100
Normalized name: sildenafil 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 100 mg orodispersible film
Study: 28442892
Drug: Film-coated 100
Normalized name: flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Film-coated 100 mg tablet (Viagra®)
Study: 25487006
Drug: Manual pressure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual pressure before benzathine penicillin injection